Marizyme, Inc. (MRZM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Marizyme, Inc. (MRZM) trades at $0.0003 with AI Score 51/100 (Grade B). Marizyme, Inc. is a life science company developing medical technologies, including DuraGraft for vascular surgeries and a Krillase-based platform for various therapeutic applications. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for MRZM: MRZM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MRZM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MRZM: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Marizyme, Inc. (MRZM) Healthcare & Pipeline Overview
Marizyme, Inc. is a Florida-based life science company specializing in medical technology development. Its portfolio includes DuraGraft, an intraoperative vascular graft treatment, and a Krillase protease-based therapeutic platform targeting complex wounds, stroke, and deep vein thrombosis. The company also advances a point-of-care diagnostic for chronic kidney disease.
What Is the Investment Thesis for MRZM?
Marizyme, Inc. presents an investment profile centered on its diverse pipeline of medical technologies, targeting significant unmet needs within the healthcare sector. The company's core value proposition stems from its proprietary platforms: DuraGraft, a vascular graft treatment; the multi-faceted Krillase protease-based therapeutic platform; and the MATLOC diagnostic device for chronic kidney disease. DuraGraft addresses critical complications in vascular surgeries, while the Krillase platform offers broad therapeutic potential across wound care, stroke, DVT, and oral hygiene. The MATLOC device aims to provide a crucial point-of-care solution for CKD assessment. Financially, Marizyme operates with a market capitalization of $0.00B and a profit margin of -10767.8%, indicative of a development-stage biotechnology company heavily investing in research and development. A gross margin of 37.0% suggests some revenue generation, likely from early commercialization or specific product sales, though overall profitability remains negative due to substantial operational expenses. The company's lean structure, with 13 employees, allows for focused R&D but also highlights the need for efficient resource allocation and potential future capital raises. Key growth catalysts include successful clinical trial outcomes, regulatory approvals for its pipeline products, and the establishment of strategic commercialization partnerships. The beta of 0.98 indicates its stock price generally moves in line with the broader market, despite its micro-cap status.
Based on FMP financials and quantitative analysis
MRZM Key Highlights
Market Capitalization: $0.00B, reflecting its status as a micro-cap or pre-revenue stage company.
- Profit Margin: -10767.8%, indicative of significant research and development expenditures typical for a development-stage biotechnology firm.
- Gross Margin: 37.0%, suggesting some revenue generation with a positive margin on goods or services sold.
- Employee Count: 13, highlighting a lean operational structure focused on specialized R&D and commercialization efforts.
- Beta: 0.98, indicating that the company's stock price volatility closely aligns with that of the broader market.
Who Are MRZM's Competitors?
MRZM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MRZM's Key Strengths?
Proprietary technology platforms (DuraGraft, Krillase, MATLOC) addressing diverse medical needs.
- Diverse product pipeline targeting significant therapeutic areas such as vascular surgery, wound care, and diagnostics.
- Focus on developing innovative solutions for unmet medical needs in healthcare.
- Lean operational structure with 13 employees, potentially allowing for agility in R&D.
What Are MRZM's Weaknesses?
Significant negative profit margin (-10767.8%) indicating substantial operational losses.
- Small market capitalization ($0.00B) and reliance on successful R&D outcomes.
- Limited public disclosure and transparency due to OTC Other listing.
- Potential resource constraints given the small employee base for a multi-platform biotech company.
What Could Drive MRZM Stock Higher?
Achievement of significant regulatory milestones for DuraGraft, potentially expanding its market access or indications.
- Positive clinical data readouts or advancements in the development of Krillase-based therapeutics for specific applications like stroke or wound care.
- Successful development and initial market introduction of the MATLOC point-of-care diagnostic device for chronic kidney disease assessment.
- Formation of strategic partnerships or licensing agreements that could accelerate the commercialization or further development of its proprietary platforms.
What Are the Key Risks for MRZM?
Financial-distress signal — its Altman Z-Score of -14.73 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin (-10767.8%) indicating substantial operational losses typical for a development-stage biotech, requiring continuous capital infusion.
- Failure to secure necessary regulatory approvals for its pipeline products, including DuraGraft, Krillase-based therapies, and MATLOC, which would impede commercialization.
- Intense competition within the biotechnology and medical technology sectors from larger, well-funded companies with established market presence and R&D capabilities.
- Challenges in securing adequate funding or experiencing significant dilution to finance ongoing research, development, and eventual commercialization efforts.
- Clinical trial failures or unexpected adverse events during product development, which could delay or halt the progress of its therapeutic platforms.
What Are the Growth Opportunities for MRZM?
- DuraGraft Market Penetration: The global market for vascular grafts is substantial, driven by the increasing incidence of cardiovascular diseases and an aging population requiring bypass and vascular repair surgeries. DuraGraft, as a one-time intraoperative treatment designed to maintain endothelial function and structure, offers a compelling value proposition by potentially reducing complications and improving long-term graft patency. Successful commercialization and widespread adoption of DuraGraft in major surgical centers could unlock significant revenue streams. The timeline for this opportunity is ongoing, contingent on regulatory clearances and market acceptance, with potential for steady growth as clinical evidence and surgeon experience accumulate, establishing it as a standard of care in its niche.
- Krillase Platform Therapeutic Expansion: Marizyme's Krillase protease-based therapeutic platform holds immense potential due to its diverse applicability across multiple high-value medical indications. This includes complex wounds and burns, acute ischemic stroke, and deep vein thrombosis, each representing multi-billion dollar markets with significant unmet needs for more effective treatments. Further development and successful clinical trials for these varied applications could lead to a broad portfolio of Krillase-based products. The timeline for realizing this opportunity is staggered, with each indication requiring independent clinical and regulatory pathways, offering multiple future catalysts for value creation and market entry over the next several years.
- MATLOC Point-of-Care Diagnostic Launch: The development of MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device for chronic kidney disease (CKD), addresses a critical need for accessible and early CKD assessment. The global market for kidney disease diagnostics is expanding rapidly, driven by the rising prevalence of CKD and the push for preventative care. Launching MATLOC could position Marizyme as an innovator in decentralized diagnostics, offering convenience and efficiency. This opportunity is upcoming, with market entry dependent on successful device development, regulatory clearance, and establishing distribution channels, potentially within the next 3-5 years, tapping into a growing demand for rapid diagnostic tools.
- Ischemia Reperfusion Injury Mitigation: Marizyme's focus on developing products to mitigate ischemia reperfusion injury (IRI) in grafting and transplantation surgeries, as well as other indications, represents a significant growth area. IRI is a major cause of organ damage and graft failure, impacting outcomes in a wide range of surgical procedures. A successful therapeutic solution in this area could have broad application across transplant medicine, cardiovascular surgery, and trauma. The market for solutions addressing IRI is substantial, driven by the volume of such procedures globally. This opportunity is long-term, requiring extensive research and development, but offers the potential for a platform technology with widespread clinical utility.
- Strategic Partnerships and Licensing Agreements: Given Marizyme's lean operational structure and focus on innovative R&D, forming strategic partnerships or licensing agreements for its proprietary technologies represents a crucial growth pathway. Collaborations with larger pharmaceutical or medical device companies could provide necessary funding, accelerate clinical development, and leverage established commercialization infrastructures. Such alliances could significantly de-risk product development and expand market reach for DuraGraft, the Krillase platform, or MATLOC. The timeline for these opportunities is ongoing, as biotech companies frequently seek partnerships at various stages of product development to maximize market potential and share development costs.
What Are MRZM's Competitive Advantages?
- Proprietary medical technology platforms, including DuraGraft, the Krillase protease-based system, and the MATLOC diagnostic device.
- Targeting specific, unmet medical needs in areas such as vascular surgery, complex wound care, stroke, and chronic kidney disease.
- Specialized scientific expertise in protease-based therapeutics and lab-on-chip diagnostic device development.
- Potential for intellectual property protection around its unique technologies and applications.
What Does MRZM Do?
Marizyme, Inc., incorporated in 2007 and headquartered in Jupiter, Florida, initially operated as GBS Enterprises Incorporated before its rebranding. As a dedicated life science company, Marizyme focuses on the rigorous development and strategic commercialization of advanced medical technologies designed to address critical unmet needs in healthcare. A cornerstone of its product portfolio is DuraGraft, an innovative one-time intraoperative vascular graft treatment. This solution is specifically engineered for use in complex vascular and bypass surgeries, with its primary function being to preserve endothelial function and structure, alongside other vital properties of the graft, thereby aiming to improve long-term patency and patient outcomes. Beyond DuraGraft, Marizyme possesses a versatile Krillase protease-based therapeutic platform, representing a significant area of its developmental efforts. This platform is being leveraged across a diverse range of therapeutic applications, including the treatment of complex wounds and severe burns, acute ischemic stroke, and deep vein thrombosis. Furthermore, the Krillase technology is also being explored for its potential in oral health, specifically for dissolving plaque and biofilms on teeth, showcasing its broad applicability. The company's research and development pipeline also extends to mitigating the detrimental effects of ischemia reperfusion injury, a critical concern in various grafting and transplantation surgeries, as well as other related medical indications. In a strategic move to diversify its offerings into diagnostics, Marizyme is actively developing MATLOC. This point-of-care, lab-on-chip digital screening and diagnostic device platform is designed for the precise assessment of chronic kidney disease (CKD). The development of MATLOC underscores Marizyme's commitment to providing accessible and efficient diagnostic tools, complementing its therapeutic innovations. With its lean team of 13 employees, Marizyme navigates the complex landscape of medical technology, striving to bring its innovative solutions from development to market. The company's strategic focus spans both interventional treatments and diagnostic tools, positioning it within the dynamic biotechnology and medical device sectors.
What Products and Services Does MRZM Offer?
- Develops and commercializes advanced medical technologies.
- Offers DuraGraft, an intraoperative vascular graft treatment for bypass and vascular surgeries.
- Utilizes its Krillase protease-based platform for treating complex wounds and burns.
- Applies the Krillase platform for acute ischemic stroke and deep vein thrombosis therapies.
- Explores Krillase technology for dissolving plaque and biofilms on teeth.
- Focuses on developing products to mitigate ischemia reperfusion injury in various surgeries.
- Develops MATLOC, a point-of-care digital diagnostic device for chronic kidney disease assessment.
How Does MRZM Make Money?
- Primarily focused on the research, development, and commercialization of proprietary medical technologies.
- Potential revenue generation from direct sales of its medical devices and therapeutic products, such as DuraGraft.
- Future revenue streams anticipated from the market introduction of Krillase-based therapeutics and the MATLOC diagnostic device.
- Potential for licensing agreements or strategic partnerships to facilitate the development, manufacturing, and distribution of its technology platforms.
What Industry Does MRZM Operate In?
Marizyme, Inc. operates within the highly innovative and competitive biotechnology and medical technology sectors, focusing on areas such as vascular surgery, advanced wound care, neurological interventions, and diagnostics. The broader healthcare industry is characterized by a continuous demand for novel solutions that improve patient outcomes, reduce healthcare costs, and enhance diagnostic capabilities. Marizyme's development of DuraGraft positions it within the vascular graft market, which is driven by an aging population and increasing prevalence of cardiovascular diseases. Similarly, its Krillase platform targets substantial markets in wound care, stroke treatment, and deep vein thrombosis, all areas with significant patient populations and ongoing needs for more effective therapies. The MATLOC device enters the burgeoning point-of-care diagnostics market for chronic kidney disease, a segment poised for growth due to the global rise in CKD incidence and the emphasis on early detection. The competitive landscape includes established pharmaceutical giants, specialized biotech firms, and medical device manufacturers, all vying for market share through R&D, clinical efficacy, and regulatory approvals. Marizyme differentiates itself through its proprietary technology platforms, aiming to carve out niches by addressing specific biological mechanisms and clinical challenges.
Who Are MRZM's Key Customers?
- Hospitals and surgical centers utilizing vascular graft treatments for bypass and vascular surgeries.
- Healthcare providers and specialists in wound care, cardiovascular health, and neurological conditions.
- Dental professionals and clinics interested in advanced oral hygiene solutions.
- Patients benefiting from improved surgical outcomes, advanced therapeutic interventions, and early disease diagnostics.
Company Profile
Marizyme, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jupiter, US. The company is led by CEO David L. Barthel. MRZM has traded publicly since 2010.
MRZM Valuation & Market Position
Relative to its peer group, MRZM's quantitative score of 51/100 is below the peer average of 76/100.
Financial Health
Marizyme, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.73 places it in the distress zone, a signal of elevated financial risk.
MRZM Financials
Bull Case vs Bear Case
Bull Case
- Proprietary technology platforms (DuraGraft, Krillase, MATLOC) addressing diverse medical needs.
- Diverse product pipeline targeting significant therapeutic areas such as vascular surgery, wound care, and diagnostics.
- Focus on developing innovative solutions for unmet medical needs in healthcare.
- Lean operational structure with 13 employees, potentially allowing for agility in R&D.
Bear Case
- Significant negative profit margin (-10767.8%) indicating substantial operational losses.
- Small market capitalization ($0.00B) and reliance on successful R&D outcomes.
- Limited public disclosure and transparency due to OTC Other listing.
- Potential resource constraints given the small employee base for a multi-platform biotech company.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | $32,855 | -$6M | -$0.05 |
Based on FMP financials and quantitative analysis
MRZM Latest News
No recent news available for MRZM.
MRZM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MRZM.
Price Targets
Wall Street price target analysis for MRZM.
MRZM MoonshotScore
What does this score mean?
The MoonshotScore rates MRZM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David L. Barthel
Chief Executive Officer
David L. Barthel serves as the Chief Executive Officer of Marizyme, Inc., overseeing the company's strategic direction and operational execution. His leadership encompasses managing a team of 13 employees, guiding the development and commercialization efforts for Marizyme's portfolio of medical technologies. Specific details regarding his educational background, prior executive roles, or extensive career history beyond his current position at Marizyme are not provided in the available source data. His role involves steering the company's initiatives in the life science sector, focusing on bringing innovative solutions to market.
Track Record: Under David L. Barthel's leadership, Marizyme, Inc. has continued its focus on advancing its key medical technology platforms, including DuraGraft, the Krillase protease-based therapeutic platform, and the MATLOC diagnostic device. While specific achievements such as major product launches, significant clinical milestones, or financial turnarounds are not detailed in the provided information, his tenure is marked by the ongoing development and strategic positioning of these diverse product candidates within the competitive healthcare landscape.
MRZM OTC Market Information
Marizyme, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the over-the-counter market. Companies in this tier typically have limited or no public disclosure requirements with the SEC, unlike those listed on major exchanges like NYSE or NASDAQ, or even higher OTC tiers like OTCQX or OTCQB. This classification signifies that investors have access to less comprehensive and less frequent financial and operational information, leading to higher inherent risks. It often indicates a company that is very early-stage, has minimal operations, or is not in compliance with higher listing standards.
- OTC Tier: OTC Other
- Limited public disclosure and transparency, making informed investment decisions challenging for investors.
- Extremely low trading liquidity, leading to wide bid-ask spreads and potential difficulty in executing trades efficiently.
- High price volatility due to low trading volume and the speculative nature often associated with OTC Other securities.
- Increased susceptibility to market manipulation due to limited oversight and a potentially low public float.
- Difficulty in raising capital through traditional means, potentially leading to highly dilutive financing rounds.
- Verify any available financial statements and reports, even if informal or non-standardized.
- Research management's background, experience, and any past performance in public companies.
- Assess the current stage of product development, clinical trial progress, and regulatory pathways for all pipeline assets.
- Investigate any news, press releases, or corporate actions directly from the company's official channels.
- Understand the competitive landscape and the addressable market potential of its medical technologies.
- Evaluate the company's capital structure, outstanding shares, and potential for future equity dilution.
- Consult legal counsel regarding the specific risks and regulatory environment associated with OTC Other securities.
- Incorporated in 2007, indicating a sustained operational history over more than a decade.
- Headquartered in Jupiter, Florida, US, suggesting a physical presence and operational base.
- Has a named Chief Executive Officer, David L. Barthel, providing clear leadership.
- Possesses a specific and detailed product pipeline (DuraGraft, Krillase, MATLOC) demonstrating active research and development.
- Focuses on tangible medical technologies with defined applications rather than purely speculative ventures.
MRZM Healthcare Stock FAQ
What does the AI Score mean for MRZM?
MRZM holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Marizyme, Inc. is a life science company developing medical technologies, including DuraGraft for vascular surgeries and a Krillase-based platform for various therapeutic applications. The company …
What are Marizyme, Inc.'s primary medical technology platforms and their applications?
Marizyme, Inc. is actively developing and commercializing several distinct medical technology platforms. Its flagship product, DuraGraft, is an intraoperative vascular graft treatment used in bypass and vascular surgeries, designed to maintain endothelial function and structure.
How does Marizyme, Inc. navigate regulatory approval processes for its medical products?
As a life science company focused on developing and commercializing medical technologies, Marizyme, Inc. operates within a highly regulated environment. The process for bringing products like DuraGraft, Krillase-based therapeutics, and the MATLOC diagnostic device to market typically involves rigorous pre-clinical testing, multiple phases of clinical trials, and submission for approval to regulatory bodies such as the FDA in the United States or EMA in Europe.
What are the key financial characteristics of Marizyme, Inc. as a development-stage company?
Marizyme, Inc. exhibits financial characteristics typical of a development-stage biotechnology company focused on research and commercialization rather than immediate profitability. The company currently reports a market capitalization of $0.00B, reflecting its micro-cap status.
What are the key factors to evaluate for MRZM?
Marizyme, Inc. (MRZM) holds an AI score of 51/100 (moderate). presents an investment profile centered on its diverse pipeline of medical technologies, targeting significant unmet needs within the healthcare sector. Not financial advice.
How frequently does MRZM data refresh on this page?
MRZM's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MRZM's recent stock price performance?
Marizyme, Inc. (MRZM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology platforms (DuraGraft, Krillase, MATLOC) addressing diverse medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MRZM overvalued or undervalued right now?
Marizyme, Inc. (MRZM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MRZM before investing?
Before investing in Marizyme, Inc. (MRZM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to the provided source data.
- Specific details on product development stages, clinical trial results, and regulatory timelines are not available in the source.
- CEO background and track record are not detailed in the provided data.